Your browser doesn't support javascript.
loading
IV Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
New Egyptian Journal of Medicine [The]. 2005; 33 (3): 135-142
in English | IMEMR | ID: emr-73885
Responsible library: EMRO
ABSTRACT
The rapid progress in the field of interventional cardiology in the last few years necessitates a continuous search for the most safe and effective methods to gain an optimum results, either equipments or drugs. to examine the use of enoxaparin as an anticoagulant in elective PCI, and compare it with unfractionated heparin regarding the acute procedural complications and the immediate 24-hour post-PCI events. The study was conducted on 84 patients who were classified independently into 2 groups. 50 patients represent group [A], received IV single bolus of enoxaparin in a dose of 0.5mg/kg at the start of the procedure and 34 patients represent group [B], received the usual traditional dose of unfractionated heparin [10000-15000 units].All patients were prepared by clopidogrel or ticlopidin before PCI in addition to aspirin 150 mg daily.Follow up was done for all patients during the immediate 24 hours after PCI for death, myocardial infarction, myocardial ischemia requiring urget coronary intervention and cerobrovascular stroke. There was no statistical significant difference between the two groups regarding the type of vessels treated or number of stents placed. None of the patients of both groups experienced any of the following complications during the procedure or 24 hours after major bleeding, myocardial infarction, myocardial ischemia requiring urgent surgical or repeat percutaneous coronary revascularization or death. The major difference between the two groups was the immediate sheath removal in the enoxaparin group, without sheath site complication [minor haematoma] which was observed in 9% of the UFH group. Angiographic complications were coronary artery dissection [in one patient in group A [2%] and 3 patients in group B [9%]] and acute closure of the culprit vessel [occurred in one patient in group A [2%] and none in group B. The results were quite encouraging, with no statistical differences between the two arms of the study regarding the acute complications and the clinical outcome. The use of enoxaparin in this reduced dose is feasible in elective PCI with adequate level of anticoagulation without need for monitoring its anticoagulant effect. The early sheath removal in group A necessitates further studies to assess its impact on the duration of hospital stay and the possibility of early discharge of the patients
Subject(s)
Search on Google
Index: IMEMR (Eastern Mediterranean) Main subject: Heparin / Smoking / Risk Factors / Treatment Outcome / Enoxaparin / Diabetes Mellitus / Hyperlipidemias / Hypertension Limits: Female / Humans / Male Language: English Journal: New Egypt. J. Med. Year: 2005
Search on Google
Index: IMEMR (Eastern Mediterranean) Main subject: Heparin / Smoking / Risk Factors / Treatment Outcome / Enoxaparin / Diabetes Mellitus / Hyperlipidemias / Hypertension Limits: Female / Humans / Male Language: English Journal: New Egypt. J. Med. Year: 2005